Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(04): 349-354
DOI: 10.1055/s-0041-1732859
Original Article

A Retrospective Observational Study of Dicentric (9;12): A Unique, Nonrandom Translocation Defining a Cytogenetic Subgroup with Favorable Outcome in Acute Lymphoblastic Leukemia

S. Shanthala
1   Cytogenetics Unit-Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
B. L. Kavitha
1   Cytogenetics Unit-Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
Prasanna Kumari
1   Cytogenetics Unit-Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
C.R. Vijay
2   Department of Biostatistics, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
D. Lokanatha
3   Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
L. Appaji
4   Department of Pediatric Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
Govind Babu
3   Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
C. S. Premalata
5   Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
,
C. Ramachandra
6   Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
› Institutsangaben

Funding None.
Preview

Abstract

Introduction Cytogenetic abnormalities are integral to the risk stratification of acute lymphoblastic leukemia (ALL).

Objectives The present study aimed to highlight a rare, yet nonrandom cytogenetic abnormality notably dicentric (9;12), which was observed in ALL patients who presented to our institute. The study analyzed the frequency, clinicohematological features, and treatment response of these patients.

Materials and Methods A single-group observational study was conducted from April 2014 to April 2020. Cytogenetic analysis was done on bone marrow aspirate samples of the patients referred to the cytogenetics laboratory with clinical diagnosis of acute leukemia. Cytogenetic, clinical, and hematological data were collected from respective departmental records, case files, and patients.

Results Dic(9;12) was identified in 1.2% of ALL (19 out of 1,544 patients). They showed striking preponderance in teen and young adult males with characteristic precursor B cell immunophenotype. Majority of these patients displayed favorable risk profiles such as low total count, mild lymphadenopathy and splenomegaly, mild-to-moderate elevation of lactate dehydrogenase, and good response to first induction chemotherapy. Rare coexistence of dic(9;12) with well-established cytogenetic markers such as t(9;22) and t(1;19) was observed.

Conclusion Dic(9;12) is one of the most specific cytogenetic markers of precursor B cell (pre-B) ALL. It defines a subgroup with favorable clinical and biological profile. We suggest inclusion of dic(9;12) in cytogenetic risk stratification of precursor B cell ALL. Long-term follow-up studies are recommended to establish the prognostic significance of this cytogenetic subgroup, which may benefit from less intensive chemotherapy.



Publikationsverlauf

Artikel online veröffentlicht:
05. Oktober 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India